Chemomab Therapeutics (CMMB) Competitors

Chemomab Therapeutics (NASDAQ:CMMB) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Do institutionals & insiders hold more shares of CMMB or BCEL?

23.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 34.9% of Atreca shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 11.3% of Atreca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community prefer CMMB or BCEL?

Atreca received 85 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 50.00% of users gave Chemomab Therapeutics an outperform vote.

Company	Underperform	Outperform
Chemomab Therapeutics	Outperform Votes 10 50.00%	Underperform Votes 10 50.00%
Atreca	Outperform Votes 95 67.86%	Underperform Votes 45 32.14%

Which has more risk & volatility, CMMB or BCEL?

Chemomab Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Atreca has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Is CMMB or BCEL more profitable?

Chemomab Therapeutics' return on equity of -101.15% beat Atreca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-101.15%	-84.19%
Atreca	N/A	-120.73%	-58.69%

Does the media prefer CMMB or BCEL?

In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.37 beat Atreca's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemomab Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atreca	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger valuation & earnings, CMMB or BCEL?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$27.65M	-$2.94	-0.30
Atreca	N/A	N/A	-$97.16M	-$2.18	-0.12

Do analysts recommend CMMB or BCEL?

Chemomab Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 695.64%. Atreca has a consensus price target of $10.75, indicating a potential upside of 4,125.63%. Given Atreca's stronger consensus rating and higher probable upside, analysts clearly believe Atreca is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atreca	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Atreca beats Chemomab Therapeutics on 10 of the 14 factors compared between the two stocks.